Core Insights - Oracle's new health system operations suite enhances hospitals' ability to make quick and effective decisions during emergencies, improving patient and staff support [1][3] - The suite includes features like Oracle Health Patient Flow and Command Center Dashboard, which facilitate mass transfers, bed management, and evacuation planning [1][2] - These emergency management capabilities will be available at no cost to existing health systems operations customers [2] Group 1: New Capabilities - The new capabilities allow for batch actions by bed management teams, improving efficiency in mass patient transfers and enhancing situational awareness [3][4] - Hospitals can dynamically manage bed visibility, creating disaster beds as needed and prioritizing patient movement during emergencies [4] Group 2: Collaboration and Implementation - Customers such as MedStar Health and BayCare Health collaborated with Oracle Health to develop these new features [1] - The solutions aim to transform health systems into real-time operations, optimizing patient journeys and resource coordination [2]

Core Insights - Amazon is expanding its palm-scanning payment system, Amazon One, to Whole Foods and NYU Langone Health facilities, marking a significant step in its technology deployment in retail and healthcare sectors [1][5]. Group 1: Amazon One Technology - Amazon One is a contactless service that allows for secure and quick identification of patients, aimed at improving efficiency in healthcare settings [2]. - The technology was first introduced in Amazon Go stores in 2020 and has since been rolled out to all Whole Foods Market locations in 2023 [6]. Group 2: NYU Langone Health Implementation - NYU Langone Health, which handles over 10 million patient visits annually, expects to reduce patient check-in times from 2-3 minutes to under 1 minute with Amazon One [3]. - The collaboration between Amazon and NYU Langone has been in development for approximately nine months, making NYU Langone the first healthcare organization to implement Amazon One [5]. Group 3: Benefits and Future Applications - The implementation of Amazon One is anticipated to enhance patient experience by reducing wait times and administrative workload for staff [4]. - Future applications of Amazon One in healthcare may include credentialing for access to secure areas and shared computer systems [5].

Core Viewpoint - CVS Health has shown signs of recovery with strong earnings, but concerns about its financial health and operational challenges remain prevalent [2][3][4]. Financial Performance - CVS Health reported revenue of $97.7 billion, exceeding expectations of $97.2 billion, and adjusted earnings per share of $1.19, surpassing the forecast of $0.93 [3]. - The stock has increased by 40% in 2025, significantly outperforming the S&P 500's 2% gain during the same period [2]. Operational Challenges - The company's medical benefits ratio (MBR) rose to 94.8%, up from 88.5% in the previous year, indicating worsening margins due to increased utilization and declining Medicare Advantage ratings [4]. - All three main operating units—healthcare benefits, health services, and pharmacy and consumer wellness—reported lower adjusted operating income compared to the previous year [5]. Market Sentiment - Despite beating expectations, analysts suggest that the low expectations may have influenced the positive results, making it difficult to predict CVS's future performance [6]. - The stock is currently trading at around 11 times its expected future earnings, which may appear attractive but is based on uncertain analyst expectations [7]. Investment Considerations - Investors are advised to be cautious, as the high MBR and overall business condition indicate that CVS has not fully turned around [8]. - A wait-and-see approach is recommended to monitor MBR trends over the next few quarters for signs of improvement [9].

Financial Data and Key Metrics Changes - For Q4 2024, Medicare Advantage (MA) membership increased by 36% year-over-year to 527,000 members, driven by the expansion of the '24 partner class and 4.1% same geography growth [10][30] - Total revenue grew 44% to $1.52 billion for the quarter and $6.06 billion for the year, primarily driven by the class of '24 and organic growth in existing classes [11][31] - Medical margin was $1 million for Q4 2024, compared to a negative margin of $102 million in Q4 2023, while the full-year medical margin was $205 million, down from $299 million in 2023 [34] - Adjusted EBITDA was negative $84 million for Q4 2024 and negative $154 million for the full year, reflecting elevated medical cost trends and unfavorable prior year development [12][37] Business Line Data and Key Metrics Changes - ACO model membership reached 132,000 members at the end of Q4 2024, representing a 48% year-over-year growth [30] - The company anticipates a full-year MA membership decline of approximately 4% for 2025, projecting a range of 490,000 to 520,000 members [14][41] - ACO model business is projected to have 110,000 members in 2025, as the company exits one underperforming MSSP partnership [14][41] Market Data and Key Metrics Changes - The Medicare Advantage market continues to experience elevated cost trends, with a gross medical cost trend of 6.3% expected for 2025 [16][48] - The company has reduced its Medicare Part D exposure to less than 30% of its membership, reflecting a strategic decision to minimize risk in areas outside its control [56][58] Company Strategy and Development Direction - The company aims to be cash flow breakeven by 2027, focusing on strengthening its business for near-term improvement and profitability [8][50] - Strategic actions include reducing underwriting exposure, pursuing profitable growth, enhancing clinical and operational capabilities, and maintaining cost discipline [7][24] - The company is investing in clinical programs to improve quality outcomes and is focused on leveraging technology and data analytics to enhance operational performance [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a challenging macro environment for 2025 but expresses optimism about favorable trends in payor bids and the 2026 advanced notice from CMS [9][25] - The company views 2025 as a transition year, with expectations for improved financial performance in 2026 and beyond [24][28] Other Important Information - The company ended Q4 2024 with cash and marketable securities of $406 million, with an expected cash use of approximately $110 million for 2025 [39][50] - The company has exited two unprofitable partnerships, improving bottom line profitability and cash burn [27][28] Q&A Session Summary Question: Changes to Part D and Contracting for 2025 - Management discussed narrowing exposure to Part D risk, reducing it to 30% of members, and highlighted the challenges associated with this risk [56][57] Question: Year 1 Performance Expectations - Management noted strong performance from the class of '24 and indicated that the class of '25 will be smaller with a focus on measured growth [63][64] Question: Medical Cost Trend Guidance - Management clarified that the 50 basis point estimate for the 2 Midnight rule is incorporated into the cost trend guidance for 2025 [72] Question: ACO REACH Client Impact - Management confirmed that exiting an underperforming MSSP partnership was due to financial losses, impacting overall performance [79] Question: Working Capital Improvement Factors - Management highlighted disciplined cash management and partnership exits as key factors improving working capital [86][88] Question: Medical Margin Initiatives - Management expressed confidence in initiatives aimed at improving quality performance and clinical management activities [92][96] Question: 2026 MA Advance Notice - Management was encouraged by the advance notice and emphasized the need for rates to catch up with utilization trends [101][102]

Financial Data and Key Metrics Changes - For the full year 2024, same store net operating revenues increased by 5.5% and adjusted EBITDA improved by 6% [9][17] - Adjusted EBITDA for the fourth quarter was $428 million, compared to $386 million in the prior year period, with a margin of 13.1%, up from 12.1% [16][17] - Cash flows from operations were $216 million for the fourth quarter, up from $90 million in the fourth quarter of 2023, and $480 million for the full year of 2024, consistent with guidance [19][20] Business Line Data and Key Metrics Changes - Same store admissions increased by 3.2%, adjusted admissions by 2.7%, and surgeries by 1.3% for the full year 2024 [7] - Same store emergency department visits were up 1% and surgeries were up 0.9% in the fourth quarter [16] - Same store ambulatory surgery center cases increased by 14% last year [8] Market Data and Key Metrics Changes - The company completed divestitures in Cleveland, Tennessee, and Statesboro, North Carolina, with plans for additional divestitures expected to generate over $1 billion in total proceeds [10][22] - The net debt to trailing adjusted EBITDA improved to 7.4 times, down from 7.9 times at the end of 2023 [22] Company Strategy and Development Direction - The company is focused on expanding outpatient access, including primary care, specialty practices, and urgent care centers, with significant capital investments [7][15] - The implementation of a new ERP system is expected to drive efficiencies and reduce costs, with estimated savings of $40 million to $60 million in 2025 [23] - The company anticipates further expansion of internally managed hospital-based provider services in 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management noted stabilization in payer downgrades and denials, which had been a troubling trend for healthcare providers [11][17] - The company expects organic growth of $75 million to $100 million in 2025, with net revenue guidance of $12.2 billion to $12.6 billion [23] - Management expressed confidence in the approval of directed payment programs in New Mexico and Tennessee, which could add an incremental $100 million to $125 million to annual EBITDA [24][50] Other Important Information - The company experienced a $10 million impact from a hurricane in Q4, with one hospital still shut down as a result [74] - The company is in discussions for additional strategic divestitures expected to be announced soon [22] Q&A Session Summary Question: Can you help bridge 2024 to 2025 guidance? - Management provided a high-level bridge starting with 2024 EBITDA of $1.54 billion, accounting for reductions from divestitures and adding organic growth to reach the midpoint of 2025 guidance [27][28] Question: What are the strategic moves expected moving forward? - Management highlighted ongoing investments in core portfolio growth, including outpatient and procedural capacity expansions, and noted that there are still investable opportunities in the pipeline [30][33] Question: Can you quantify the continued hurricane impact in Q4? - The hurricane impact was as expected at $10 million, with one hospital shut down for the entire quarter [74]

Financial Data and Key Metrics Changes - The company reported a net revenue of $240 million for the quarter, a decrease from the prior year period, primarily due to a decline in net administrative fees revenue and supply chain services [14] - GAAP net loss from continuing operations was $46 million, mainly due to a goodwill impairment charge of $127 million related to the data and technology business in the Performance Services segment [15] - Adjusted EBITDA was $50 million, translating to a margin of 20.8%, which declined largely due to lower revenue [15] - Adjusted earnings per share was $0.25, and excluding the impact of Contigo Health, it was $0.27, in line with expectations [16] Business Line Data and Key Metrics Changes - In the Supply Chain Services segment, lower net administrative fees revenue was driven by an expected increase in the aggregate blended fee share to the low 60% level [17] - Gross administrative fees grew as existing members increased penetration of contract spend, with a growth of close to 4% overall in gross administrative fees [33] - The Performance Services segment experienced a revenue decline of 19% due to lower demand in consulting services and an unfavorable product mix in Applied Sciences [18] Market Data and Key Metrics Changes - The company is seeing a shift in member interest favoring SaaS subscription engagements versus license agreements in the Performance Services segment [19] - The company expects to address greater than 75% of the fees from the group of GPO members by the end of fiscal year 2025 [18] Company Strategy and Development Direction - The company is focused on technology enabling performance improvement and supply chain excellence for healthcare, with a strategy that includes AI enabling manual back office processes and enhancing data for actionable insights [9] - The company is committed to diversifying its supplier base to build resiliency in the supply chain and mitigate potential tariff impacts [28] - The leadership transition in the Performance Services segment aims to reinvigorate the business by recruiting new talent and refocusing solutions around key areas of differentiation [10][11] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the long-term strategy despite short-term headwinds in the Performance Services segment [19] - The company is encouraged by the growing demand for provider-focused data and market intelligence, which is seen as a key differentiator in the market [10] - Management believes they are well-positioned for continued success with a flexible balance sheet and meaningful cash flow [24] Other Important Information - The company completed the sale of the network assets of Contigo Health for $15 million and is working towards divesting remaining assets [13][88] - Free cash flow for the first half of fiscal year 2025 was $74 million, an increase of $33 million from the prior year period [20] Q&A Session Summary Question: What are the discussions regarding tariffs and how are you preparing customers? - The company is focusing on building resiliency and diversification of suppliers in the supply chain to mitigate tariff impacts [28] Question: Can you provide insights on the dynamics behind net administrative fees? - The company is seeing good growth in gross administrative fees and is making progress in renegotiating contracts [32] Question: What is the expectation for the Performance Services segment in the second half of the year? - The company expects stronger performance in the second half due to a strong funnel in applied sciences and timing of enterprise license agreements [55] Question: Can you clarify the nature of the $17.6 million distribution from the minority investment? - The distribution was one-time and did not come from Omnia, and it has been adjusted out of the numbers [67] Question: How does the firm for term pricing work in relation to tariffs? - The firm for term pricing is embedded in supplier contracts, meaning suppliers absorb the tariffs, not the company or its customers [76]

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDIROM HEALTHCARE TECHNOLOGIES INC. Table of Contents As filed with the U.S. Securities and Exchange Commission on August 23, 2024. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) Japan 8000 Not Applicable (Primary Standard Industrial Classification Code Number) MEDIROM Healthcare ...

Table of Contents As filed with the Securities and Exchange Commission on March 14, 2024. Registration No. 333-276435 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Auna S.A. (Exact Name of Registrant as Specified in Its Charter) Grand Duchy of Luxembourg 8011 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. ...

Table of Contents As filed with the Securities and Exchange Commission on February 22, 2024. Registration No. 333-276435 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Auna S.A. (Exact Name of Registrant as Specified in Its Charter) Grand Duchy of Luxembourg 8011 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R ...

Table of Contents TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Auna S.A. (Exact Name of Registrant as Specified in Its Charter) Grand Duchy of Luxembourg 8011 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) As filed with the Securities and Exchange Commission on January 25, 2024. Registration No. 333-276435 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 (Primary Standard Industrial Classification Code Number) (I.R. ...